Philips expanded ventilator recall classified as most serious by USFDA
A Philips supplier had incorrectly used a type of polyurethane foam in one of the parts of Trilogy Evo ventilators - an issue that was identified during lab testing, the regulator said.
New Delhi: The U.S. Food and Drug Administration (FDA) on Wednesday classified an expanded recall of certain ventilators by Philips late last year as Class 1, or the most serious type, saying they could lead to injuries or death.
The Dutch medical equipment company initiated the recall of 215 Trilogy Evo ventilators and 51 repair kits in the United States in December due to potential health risks from a type of foam used in the devices.
So far, there have been no reported injuries or deaths from the products, which were distributed in the United States and Korea, the FDA said.
"We have already reached the majority of affected customers and we will correct this issue via a repair (replacement of the foam) on site in the coming months" a company spokesperson said in an emailed statement to Reuters.
This is the latest recall by Philips to be labeled Class 1 after it pulled back up to 4 million breathing-aid machines last year amid concerns that a polyurethane foam used in the devices could degrade and become toxic.
Read also: Philips, USFDA in talks post new ventilator findings
Earlier this month, the company raised that estimate by 1 million.
A Philips supplier had incorrectly used a type of polyurethane foam, which is intended to reduce sound and vibration, in one of the parts of the Trilogy Evo ventilators - an issue that was identified during lab testing, the regulator said on Wednesday.
The supplier used polyester-based polyurethane foam instead of a polyether-based one which is specified for these products and meets all applicable standards, Philips said in the email.
The polyester-based foam could break down and potentially enter the device's air pathway, leading to the user inhaling chemicals or other harmful materials, the FDA said.
Read also: Philips ventilator recall troubles deepen as USFDA finds new issues
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.